Mersana Therapeutics Inc.

MRSN | NASDAQ

Price Alert Chart Builder DCF Calculator

$29.08

$0 (0.00%)

At close: Jan 6, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Key Statistics

Market Data

Market Cap $145.36M

1D Range

28.78 29.08

52W Range

5.21 30.39

Valuation (TTM)

PE -2.06

PB -2.44

EV/EBITDA -1.54

Valuation (NTM)

Forward PE N/A

Forward PEG 0.43

Price Target $10

Cash Flow

FCF Yield -51.2%

SBC Adj. FCF Yield -57.5%

SBC Impact -12.5%

Margins

Gross Margin 98.3%

Operating Margin -180.5%

FCF Margin -224.1%

Growth (CAGR)

Revenue 3Y | 5Y 40.7% | 107.6%

Dil EPS 3Y | 5Y 61.8% | 33.1%

FCF 3Y | 5Y 48.1% | 2.6%

Returns

ROA -89.3%

ROE 117.0%

ROIC -242.1%

Financial Health

Net Cash

$54.1M

Current Ratio 1.39

Interest Coverage -28.52

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting N...

Sector Healthcare

Industry Biotechnology

Employees 102

IPO Date Jun 27, 2017

Website www.mersana.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$10

Downside

-65.61%

Buy (0)

Hold (3)

Sell (0)

Analyst Details ➞